Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 8/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11575541 | 0.87 | ELANE (0.46) | TTRELANELDHAALDH1A1TSHR | |
| SCHEMBL108422 | 0.81 | LDHA (0.64) | TTRIDO1HDAC3EP300KAT2B | |
| SCHEMBL636440 | 0.79 | TTR (0.50) | TTRIDO1HDAC3EP300KAT2B | |
| SCHEMBL38143 | 0.79 | TTR (0.50) | TTRIDO1HDAC3EP300KAT2B | |
| SCHEMBL150853 | 0.79 | TTR (0.78) | TTRIDO1HDAC3EP300KAT2B | |
| SCHEMBL29516385 | 0.79 | TTR (0.78) | TTRIDO1HDAC3EP300KAT2B | |
| SCHEMBL19922628 | 0.79 | TTR (0.50) | TTRIDO1HDAC3EP300KAT2B | |
| SCHEMBL10730555 | 0.79 | TTR (0.50) | TTRIDO1HDAC3EP300KAT2B | |
| SCHEMBL1525888 | 0.79 | TTR (0.78) | TTRIDO1HDAC3EP300KAT2B | |
| SCHEMBL31603821 | 0.79 | TTR (0.50) | TTRIDO1HDAC3EP300KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1004 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117790902-A | Electrolyte containing sulfonyl fluoride compound and lithium ion battery containing electrolyte | 湖州昆仑亿恩科电池材料有限公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2023164252-A1 | ISOTHERMAL NUCLEIC ACID DETECTION ASSAYS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-31 | — | — | WO | claimed |
| CN-109342381-A | A kind of fluorescent dyeing reagent | 广州往圣生物科技有限公司 | 2019-02-15 | — | — | CN | claimed |
| US-9915665-B2 | High-throughput system and method for identifying antibodies having specific antigen binding activities | ABBVIE INC. (US) | 2018-03-13 | — | — | US | claimed |
| EP-2938636-A2 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES | AbbVie Inc. (US) | 2015-11-04 | — | — | EP | claimed |
| US-20140243228-A1 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES | ABBVIE, INC. (US) | 2014-08-28 | — | — | US | claimed |
| WO-2014106004-A2 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES | ABBVIE, INC. (US) | 2014-07-03 | — | — | WO | claimed |
| WO-2013070943-A2 | SMALL MOLECULE SCREEN FOR INHIBITORS OF NFAT:AP-1:DNA INTERACTIONS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-05-16 | — | — | WO | claimed |
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| US-20080315084-A1 | ANALYSIS METHOD OF AMINO ACID USING MASS SPECTROMETER | AJINOMOTO CO. INC (JP) | 2008-12-25 | — | — | US | claimed |
| EP-1965205-A1 | AMINO ACID ANALYSIS METHOD USING MASS SPECTROMETER | Ajinomoto Co., Inc. (JP) | 2008-09-03 | — | — | EP | claimed |
| US-5110746-A | Method for the determination of albumin in biological fluids | PHARMACIA DIAGNOSTICS INC. (US) | 1992-05-05 | — | — | US | claimed |
| EP-0287745-B1 | METHOD FOR THE DETERMINATION OF ALBUMIN IN BIOLOGICAL FLUIDS | SCHIAPPARELLI BIOSYSTEMS, INC. (US) | 1991-11-13 | — | — | EP | claimed |
| WO-1988008533-A1 | METHOD FOR THE DETERMINATION OF ALBUMIN IN BIOLOGICAL FLUIDS | ELECTRO-NUCLEONICS, INC. (US) | 1988-11-03 | — | — | WO | claimed |
| EP-0287745-A1 | Method for the determination of albumin in biological fluids | SCHIAPPARELLI BIOSYSTEMS, INC. (US) | 1988-10-26 | — | — | EP | claimed |
| WO-2026107198-A1 | ANTIBODY BIOMARKER TO DIAGNOSE IDIOPATHIC INFLAMMATORY MYOPATHIES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260125675-A1 | DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY | H LEE MOFFITT CANCER CENTER AND RESEARCH INST INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-0287745-B1 | METHOD FOR THE DETERMINATION OF ALBUMIN IN BIOLOGICAL FLUIDS | SCHIAPPARELLI BIOSYSTEMS, INC. (US) | 1991-11-13 | — | — | EP | disclosed |
| WO-1988008533-A1 | METHOD FOR THE DETERMINATION OF ALBUMIN IN BIOLOGICAL FLUIDS | ELECTRO-NUCLEONICS, INC. (US) | 1988-11-03 | — | — | WO | disclosed |
| EP-0287745-A1 | Method for the determination of albumin in biological fluids | SCHIAPPARELLI BIOSYSTEMS, INC. (US) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125675-A1 | DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY | PDCD1LG2, TRMT1L, TTLL12 | TTR 3670/4885IDO1 3541/4885HDAC3 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.